CY1117123T1 - Παραγωγα οιστρα-1,3,5(10),16-τετραενο-3- καρβοξαμιδιου, μεθοδοι για την παραγωγη αυτων, φαρμακευτικα παρασκευασματα που τα περιεχουν καθως και η χρηση αυτων για την παραγωγη φαρμακευτικων μεσων - Google Patents

Παραγωγα οιστρα-1,3,5(10),16-τετραενο-3- καρβοξαμιδιου, μεθοδοι για την παραγωγη αυτων, φαρμακευτικα παρασκευασματα που τα περιεχουν καθως και η χρηση αυτων για την παραγωγη φαρμακευτικων μεσων

Info

Publication number
CY1117123T1
CY1117123T1 CY20161100045T CY161100045T CY1117123T1 CY 1117123 T1 CY1117123 T1 CY 1117123T1 CY 20161100045 T CY20161100045 T CY 20161100045T CY 161100045 T CY161100045 T CY 161100045T CY 1117123 T1 CY1117123 T1 CY 1117123T1
Authority
CY
Cyprus
Prior art keywords
methods
ostra
tetra
products
producing
Prior art date
Application number
CY20161100045T
Other languages
English (en)
Inventor
Ulrich Bothe
Naomi Barak
Matthias Busemann
Oliver Martin Fischer
Andrea Rotgeri
Isabella Gashaw
Ingo Hartung
Tobias Marquardt
Original Assignee
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117123(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Intellectual Property Gmbh filed Critical Bayer Intellectual Property Gmbh
Publication of CY1117123T1 publication Critical patent/CY1117123T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση αφορά AKR1C3 αναστολείς και μεθόδους για την παραγωγή αυτών, την χρήση αυτών για την θεραπευτική αγωγή και/ή προφύλαξη παθήσεων, καθώς και την χρήση αυτών για την παραγωγή φαρμακευτικών μέσων για την θεραπευτική αγωγή και/ή προφύλαξη παθήσεων ιδίως προβλημάτων αιμορραγίας και ενδομητρίωσης.
CY20161100045T 2011-09-29 2016-01-18 Παραγωγα οιστρα-1,3,5(10),16-τετραενο-3- καρβοξαμιδιου, μεθοδοι για την παραγωγη αυτων, φαρμακευτικα παρασκευασματα που τα περιεχουν καθως και η χρηση αυτων για την παραγωγη φαρμακευτικων μεσων CY1117123T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011083725A DE102011083725A1 (de) 2011-09-29 2011-09-29 Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
EP12766636.0A EP2760878B1 (de) 2011-09-29 2012-09-24 Estra-1,3,5(10),16-tetraen-3-carboxamid-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln

Publications (1)

Publication Number Publication Date
CY1117123T1 true CY1117123T1 (el) 2017-04-05

Family

ID=46963705

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100045T CY1117123T1 (el) 2011-09-29 2016-01-18 Παραγωγα οιστρα-1,3,5(10),16-τετραενο-3- καρβοξαμιδιου, μεθοδοι για την παραγωγη αυτων, φαρμακευτικα παρασκευασματα που τα περιεχουν καθως και η χρηση αυτων για την παραγωγη φαρμακευτικων μεσων

Country Status (42)

Country Link
US (1) US9487554B2 (el)
EP (1) EP2760878B1 (el)
JP (1) JP5791810B2 (el)
KR (1) KR20140069013A (el)
CN (1) CN103827133B (el)
AP (1) AP2014007598A0 (el)
AR (1) AR088180A1 (el)
AU (1) AU2012314627B2 (el)
BR (1) BR112014007223A2 (el)
CA (1) CA2850047C (el)
CL (1) CL2014000775A1 (el)
CO (1) CO6920294A2 (el)
CR (1) CR20140144A (el)
CU (1) CU20140037A7 (el)
CY (1) CY1117123T1 (el)
DE (1) DE102011083725A1 (el)
DK (1) DK2760878T3 (el)
DO (1) DOP2014000059A (el)
EA (1) EA025518B9 (el)
EC (1) ECSP14013275A (el)
ES (1) ES2560257T3 (el)
GT (1) GT201400059A (el)
HK (1) HK1197414A1 (el)
HR (1) HRP20160050T1 (el)
HU (1) HUE026645T2 (el)
IL (1) IL231755A (el)
JO (1) JO3122B1 (el)
MA (1) MA35455B1 (el)
MX (1) MX2014003823A (el)
MY (1) MY175804A (el)
PE (1) PE20141554A1 (el)
PL (1) PL2760878T3 (el)
PT (1) PT2760878E (el)
RS (1) RS54521B1 (el)
SG (1) SG11201400144SA (el)
SI (1) SI2760878T1 (el)
TN (1) TN2014000131A1 (el)
TW (1) TWI537284B (el)
UA (1) UA107550C2 (el)
UY (1) UY34356A (el)
WO (1) WO2013045407A1 (el)
ZA (1) ZA201401568B (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20150353A1 (es) 2012-07-10 2015-03-28 Bayer Pharma AG Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
AP3826A (en) 2013-02-21 2016-09-30 Bayer Pharma Aktiengellschaft Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (akr1 c3)
WO2016037956A1 (en) * 2014-09-11 2016-03-17 Bayer Pharma Aktiengesellschaft 3-nitrogen or sulphur substituted oestra-1,3,5(10),16-tetraene akr1c3 inhibitors
US10167293B2 (en) 2016-05-26 2019-01-01 Bayer Pharma Aktiengesellschaft [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones
CZ307437B6 (cs) 2016-06-07 2018-08-22 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz
EP3269373A1 (en) * 2016-07-11 2018-01-17 Bayer Pharma Aktiengesellschaft Low-dosed oral dosage form of an akr1c3 inhibitor for treatment of diseases
TW201825478A (zh) 2016-12-19 2018-07-16 德商拜耳製藥公司 ［４－（苯基磺醯基）哌嗪－１－-基］（１ｈ－１，２，３－三唑－４-基）甲酮
EP3555101A2 (en) 2016-12-19 2019-10-23 Bayer Pharma Aktiengesellschaft [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones
US20200087284A1 (en) 2016-12-19 2020-03-19 Bayer Pharma Aktiengesellschaft [4-(phenylsulfonyl)piperazin-1-yl](1h-1, 2, 3-triazol-4-yl)methanones
EP3421483A1 (en) 2017-06-29 2019-01-02 Bayer Pharma Aktiengesellschaft Novel steroidal 17-beta heteroaryl compounds as inhibitors of akr1c3
CN108503695B (zh) * 2018-03-09 2021-06-08 南方医科大学南方医院 基于GnRH多肽衍生物的示踪剂及其制备方法和应用
CN110693892A (zh) * 2018-07-09 2020-01-17 深圳艾欣达伟医药科技有限公司 化合物用于制备预防、治疗或改善疼痛的药物的用途
CN113683648A (zh) * 2021-08-26 2021-11-23 上海皓鸿生物医药科技有限公司 一种2’-氟-2’-脱氧尿苷的合成方法及其中间体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632003A (en) 1985-07-15 1986-12-30 Kopp William L Musical instrument sound quality enhancement device
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
AU668144B2 (en) * 1992-03-31 1996-04-26 Btg International Limited 17-substituted steroids useful in cancer treatment
WO1999046279A2 (en) 1998-03-11 1999-09-16 Endorecherche, Inc. INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
CA2558014A1 (en) * 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
JP5264760B2 (ja) * 2006-11-30 2013-08-14 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング １７β−ＨＳＤインヒビターとしての置換エストラトリエン誘導体
US20110118219A1 (en) 2008-03-25 2011-05-19 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
KR101855453B1 (ko) 2010-04-27 2018-06-20 파르마 마르 에스.에이. 7(8) 위치가 불포화된 항암 스테로이드계 락톤

Also Published As

Publication number Publication date
AU2012314627A1 (en) 2014-04-10
CN103827133B (zh) 2015-11-25
RS54521B1 (en) 2016-06-30
JP5791810B2 (ja) 2015-10-07
HUE026645T2 (en) 2016-07-28
HK1197414A1 (zh) 2015-01-16
TN2014000131A1 (en) 2015-07-01
UA107550C2 (uk) 2015-01-12
JO3122B1 (ar) 2017-09-20
MX2014003823A (es) 2014-06-04
NZ622081A (en) 2015-10-30
ES2560257T3 (es) 2016-02-18
US9487554B2 (en) 2016-11-08
HRP20160050T1 (hr) 2016-02-12
CL2014000775A1 (es) 2014-08-18
TWI537284B (zh) 2016-06-11
MY175804A (en) 2020-07-09
MA35455B1 (fr) 2014-09-01
PE20141554A1 (es) 2014-10-24
CN103827133A (zh) 2014-05-28
SI2760878T1 (sl) 2016-02-29
CA2850047A1 (en) 2013-04-04
UY34356A (es) 2013-04-30
EA025518B9 (ru) 2017-10-31
ZA201401568B (en) 2016-11-30
AR088180A1 (es) 2014-05-14
CU20140037A7 (es) 2014-07-30
US20140249119A1 (en) 2014-09-04
EA025518B1 (ru) 2016-12-30
GT201400059A (es) 2015-02-17
DOP2014000059A (es) 2014-06-15
EA201490653A1 (ru) 2014-09-30
EP2760878B1 (de) 2015-10-28
BR112014007223A2 (pt) 2017-04-04
KR20140069013A (ko) 2014-06-09
JP2014527994A (ja) 2014-10-23
EP2760878A1 (de) 2014-08-06
CR20140144A (es) 2014-05-16
DE102011083725A1 (de) 2013-04-04
SG11201400144SA (en) 2014-05-29
AU2012314627B2 (en) 2016-08-18
PT2760878E (pt) 2016-02-26
PL2760878T3 (pl) 2016-04-29
DK2760878T3 (en) 2016-01-25
TW201317253A (zh) 2013-05-01
CA2850047C (en) 2016-03-29
ECSP14013275A (es) 2014-04-30
CO6920294A2 (es) 2014-04-10
IL231755A (en) 2016-06-30
AP2014007598A0 (en) 2014-04-30
WO2013045407A1 (de) 2013-04-04

Similar Documents

Publication Publication Date Title
CY1117123T1 (el) Παραγωγα οιστρα-1,3,5(10),16-τετραενο-3- καρβοξαμιδιου, μεθοδοι για την παραγωγη αυτων, φαρμακευτικα παρασκευασματα που τα περιεχουν καθως και η χρηση αυτων για την παραγωγη φαρμακευτικων μεσων
CY1118588T1 (el) Νεα 5-αμινοτετραϋδροκινολινο-2-καρβοξυλικα οξεα και η χρηση τους
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
CY1120437T1 (el) Νεα ινδαζολοκαρβοξαμιδια, μεθοδοι για την παραγωγη τους, φαρμακευτικα παρασκευασματα που τα περιεχουν, καθως και η χρηση αυτων για την παραγωγη φαρμακων
CY1121793T1 (el) Εκλεκτικοι αναστολεις pi3k δελτα
CY1117183T1 (el) Διακλαδισμενα παραγωγα 3-φαινυλοπροπιονικου οξεος και η χρηση τους
CY1125436T1 (el) Αναστολεις dna-pk
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
CY1119123T1 (el) Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους
CY1120866T1 (el) Παρεμποδιστες dna-pk
CY1123996T1 (el) Υποκατεστημενα παραγωγα οξοπυριδινης
CY1118441T1 (el) Παραγωγα 5-φθορο-ν-(πυριδιν-2-υλ)πυριδιν-2-αμινης που περιεχουν μια ομαδα σουλφοξιμινης
CY1118900T1 (el) Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
CY1116871T1 (el) Παραγωγα πυρρολοτριαζινονης ως αναστολεις των ρι3κ
TN2014000175A1 (en) Novel purine derivatives and their use in the treatment of disease
PH12016500094A1 (en) Autotaxin inhibitors
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
CY1115403T1 (el) Αλκυλαμινο-υποκατεστημενες δικυανοπυριδινες και προφαρμακα τυπου εστερα αμινοξεος αυτων
MX364486B (es) Derivados de piridazinona-amidas.
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
CY1119391T1 (el) Παραγωγα οξαζολιδιν-2- ονη- πυριμιδινης
BR112015018071A2 (pt) estra-1,3,5(10),16-tetraeno-3-carboxamidas
CY1113580T1 (el) Υποκατεστημενα (οξαζολιδινον-5-υλ-μεθυλ)-2-θειοφαινο-καρβοξαμιδια και χρηση αυτων στο πεδιο της πηξης του αιματος